title: Induction of allogeneic islet tolerance in a large-animal model.
abstract: For islet allotransplantation to become a therapy widely applicable to patients with insulin-dependent diabetes, it will be important to avoid conventional immunosuppression and yet maintain long-term rejection-free islet survival. This possibility was tested in a large-animal model using mixed allogeneic chimeras established using total lymphoid irradiation (TLI) and donor-specific bone marrow transplantation (BMTX). Four recipient sex-mismatched and DLA class II-matched English springer spaniels became chimeric after TLI and donor-specific BMTX. Subsequent donor-specific renal allografts survived for more than a year. Acceptance of a donor-specific skin graft and rejection of a third-party graft demonstrated tolerance with maintenance of immunocompetence. Pancreatic microfragments containing islets were refluxed into the splenic vein of the recipient. Purified islets were placed under the capsule of spleen and liver. After 75 days, recipients underwent total native pancreatectomy. All four chimeric pancreatectomized dogs had functioning islet grafts 75 days after transplantation, evidenced by a prompt rise in serum insulin levels following an IVGTT and histological demonstration of islet tissue at the site of transplantation. After removal of the transplanted islet tissue, no insulin was released after IVGTT. In summary, intrasplenic allogeneic canine islets transplanted into chimeric dogs rendered tolerant to donor MHC survive and function for greater than 75 days in the absence of immunosuppression. This study represents proof of the concept that allogeneic islet transplants have the potential to reverse diabetes without the use of conventional immunosuppression.
authors.affiliation: National Pancreas Transplant Unit, Westmead Hospital, NSW, Australia.
authors.forename: P J
authors.initials: PJ
authors.lastname: Horton
authors.forename: W J
authors.initials: WJ
authors.lastname: Hawthorne
authors.forename: S N
authors.initials: SN
authors.lastname: Walters
authors.forename: A T
authors.initials: AT
authors.lastname: Patel
authors.forename: P J
authors.initials: PJ
authors.lastname: O'Connell
authors.forename: J R
authors.initials: JR
authors.lastname: Chapman
authors.forename: R D
authors.initials: RD
authors.lastname: Allen
mesh_terms: D000681:Amylases / Q000097:blood; D000818:Animals; D004285:Dogs; D005260:Female; D005951:Glucose Tolerance Test; D006084:Graft Rejection / Q000276:immunology / Q000473:pathology; D006085:Graft Survival / Q000276:immunology; D007108:Immune Tolerance / Q000276:immunology*; D066298:In Vitro Techniques; D007328:Insulin / Q000097:blood; D016381:Islets of Langerhans Transplantation / Q000276:immunology*; D016030:Kidney Transplantation / Q000276:immunology; D008297:Male; D023421:Models, Animal; D010180:Pancreatectomy; D013154:Spleen; D018183:Transplantation Chimera / Q000276:immunology*; D014184:Transplantation, Homologous / Q000276:immunology
chemical_list: D007328:Insulin; D000681:Amylases